Which companies overlap with Gruppo Italiano Malattie EMatologiche dell'Adulto's portfolio?

Top competitors by shared drug class: Celgene, AstraZeneca, Beijing Yongtai Ruike Biotechnology Company Ltd, Astellas Pharma Global Development, Inc., Celyad Oncology SA.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gruppo-italiano-malattie-ematologiche-dell-adulto.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Gruppo Italiano Malattie EMatologiche dell'Adulto — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gruppo Italiano Malattie EMatologiche dell'Adulto pipeline: 1 marketed, 0 filed, 4 Phase 3, 14 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 4 Phase 3 14 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ibrutinib 420 mg	Ibrutinib 420 mg	marketed
Chemotherapy + Imatinib	Chemotherapy + Imatinib	phase 3	Tyrosine kinase inhibitor + chemotherapy combination	BCR-ABL, c-KIT, PDGFR	Oncology
Ponatinib + Blinatumomab	Ponatinib + Blinatumomab	phase 3	Tyrosine kinase inhibitor, Bispecific monoclonal antibody	BCR-ABL1, CD19, CD3	Oncology
Cytarabine HD	Cytarabine HD	phase 3	Nucleoside analog; antimetabolite	DNA polymerase; incorporated into DNA	Oncology
DaunoXome	DaunoXome	phase 3	Liposomal anthracycline chemotherapy	DNA (topoisomerase II inhibitor)	Oncology

Therapeutic area mix

Oncology · 9
Infectious Diseases · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celgene · 2 shared drug classes
AstraZeneca · 1 shared drug class
Beijing Yongtai Ruike Biotechnology Company Ltd · 1 shared drug class
Astellas Pharma Global Development, Inc. · 1 shared drug class
Celyad Oncology SA · 1 shared drug class
Centre Hospitalier Universitaire Dijon · 1 shared drug class
Cephalon, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gruppo Italiano Malattie EMatologiche dell'Adulto:

Cite this brief

Drug Landscape (2026). Gruppo Italiano Malattie EMatologiche dell'Adulto — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gruppo-italiano-malattie-ematologiche-dell-adulto. Accessed 2026-05-17.